DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228

Francesca Fiorentino, Jonathan Krell, Consuelo Nohpal de la Rosa, Lee Webber, Francesca Fiorentino, Jonathan Krell, Consuelo Nohpal de la Rosa, Lee Webber

Abstract

Background: The standard initial treatment for ovarian cancer is surgery and platinum-based chemotherapy and potentially maintenance therapy with avastin or inhibitors of poly-ADP ribose polymerase (PARP). While a proportion of women are cured by this approach, the vast majority will relapse and become resistant to platinum chemotherapy either initially or on subsequent treatment. There is an unmet need to improve response to treatment and quality of life in these women. TAK228 is a novel therapy that can be added to standard treatment in the participant population and the aim of the DICE trial is to assess its effectiveness. Laboratory and clinical research has shown that these ovarian cancers may respond to the molecular target of a drug such as TAK228, and there have been studies using it in other advanced solid tumours including endometrial cancer.

Methods: One hundred twenty-four eligible women will be recruited from participating research sites in the United Kingdom (UK) and Germany. Randomised participants will receive either weekly paclitaxel alone (standard treatment, n = 62) or TAK228 plus weekly paclitaxel (n = 62) until the cancer significantly worsens; there are significant adverse events or any other protocol-defined stopping criteria. Participants will be monitored for response to treatment (using radiological imaging), adverse events and quality of life during both randomised treatment and subsequent follow-up.

Discussion: The primary objective/endpoint of the study is to compare the two treatments in terms of progression-free survival, or the length of time that each participant is alive without the cancer significantly worsening according to defined assessment criteria. If the addition of TAK228 to weekly paclitaxel chemotherapy is shown to significantly improve this statistically, and adverse events and quality of life are not significantly worse than standard treatment, then TAK228 plus weekly paclitaxel could potentially be taken forward within the context of a larger phase III trial.

Trial registration: ClinicalTrials.gov NCT03648489 . Registered on 27 August 2018.

Keywords: Ovarian cancer; Platinum-resistant; TAK228; Weekly paclitaxel.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Trial scheme/flowchart

References

    1. National Institute for Health and Care Excellence. Ovarian cancer: How common is it? . Accessed 25 Mar 2021.
    1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi: 10.1016/j.ejca.2012.12.027.
    1. Cancer Research UK. Ovarian cancer statistics. . Accessed 25 Mar 2021.
    1. Lee J-Y, Kim S, Kim YT, Lim MC, Lee B, Jung K-W, Kim JW, Park S-Y, Won Y-J. Changes in ovarian cancer survival during the 20 years before the era of targeted therapy. BMC Cancer. 2018;18(1):601. doi: 10.1186/s12885-018-4498-z.
    1. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim J-W, Park S-Y, Kim B-G, Nam J-H, Fujiwara K, Walker JL. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med. 2019;381(20):1929–1939. doi: 10.1056/NEJMoa1902626.
    1. McNeish IA, Ledermann JA, Webber L, James L, Kaye SB, Hall M, Hall G, Clamp A, Earl H, Bannerjee S, Kristeleit R, Raja F, Feeney A, Lawrence C, Dawson-Athey L, Persic M, Khan I. A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer. Ann Oncol. 2014;25(10):1988–1995. doi: 10.1093/annonc/mdu363.
    1. Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007;13(10):433–442. doi: 10.1016/j.molmed.2007.08.001.
    1. Campbell IG, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64(21):7678–7681. doi: 10.1158/0008-5472.CAN-04-2933.
    1. Li H, Zeng J, Shen K. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet. 2014;290(6):1067–1078. doi: 10.1007/s00404-014-3377-3.
    1. Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R, Peltomäki P. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer. 2007;121(4):915–920. doi: 10.1002/ijc.22768.
    1. Williams CB, Williams KA, Krie AK, De P, Dey N, Leyland-Jones B, Starks D, Rojas-Espaillat LA. Results of a phase Ib trial evaluating the safety and clinical activity of sapanisertib (TAK 228) in combination with serabelisib (TAK 117) and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer. J Clin Oncol. 2020;38(Suppl 15):3604. doi: 10.1200/JCO.2020.38.15_suppl.3604.
    1. Scambia G, Han SN, Oza AM, Colombo N, Oaknin A, Raspagliesi F, Wenham RM, Braicu EI, Jewell A, Makker V, Guerra EM, Moxley KM, Baurain J-F, Su Z, Neuwirth R, Vincent S, Sedarati F, Faller DV, Krell J. Randomized phase II study of sapanisertib (SAP) + paclitaxel (PAC) plus PAC alone in patients (pts) with advanced, recurrent or persistent endometrial cancer. J Clin Oncol. 2020;38(Suppl 15):6087. doi: 10.1200/JCO.2020.38.15_suppl.6087.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours, Revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45:228–247. doi: 10.1016/j.ejca.2008.10.026.
    1. Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J. Definitions for response and progression in ovarian vancer trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer. 2011;21:419–423. doi: 10.1097/IGC.0b013e3182070f17.
    1. U.S.Department of Health and Human Services/National Institutes of Health/National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010). . Accessed 25 Mar 2021.
    1. Jennison C, Turnbull BW. Group sequential methods with applications to clinical trials. 1st. UK: CRC/Chapman & Hall; 2000.
    1. Snapinn S, Chen MG, Jiang Q, Koutsoukos T. Assessment of futility in clinical trials. Pharm Stat. 2006;5(4):273–281. doi: 10.1002/pst.216.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다